News Celgene hopes device + drug can tackle aggressive brain tumo... Novocure's Optune will be tested alongside investigational Celgene drug marizomib.
Views & Analysis Digital health round-up: Making a difference in brain disord... Is digital the true solution to brain disorders?
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends